How CBD Works: The Science of Balance
Why We Need CBD To Feel Healthy
CBD is naturally produced in our bodies and where it plays a key role in our “endocannabinoid system.”
Cannabinoids like CBD interact with our CB1 & CB2 receptors to regulate our pain, inflammation, immune systems, mood and thinking. By supplementing with plant-based cannabinoids, we can help our body to restore a state of natural balance.
- CB1 Receptors are found primarily in the brain and through the body, where they help to regulate coordination, movement, pain, emotions, mood, thinking and appetite.
- CB2 Receptors are found primarily among the immune system, where they help to manage inflammation and muscle pain.
The Benefits of CBD – Rescuing Our Overcharged Body.
Many Canadians find themselves over-stressed and under-nourished. In these busy times, our bodies have been thrown out of balance with nature. As a result, many of us may have endocannabinoids systems that simply aren’t working fully.
Clinical Endocannabinoid Deficiency Syndrome (CEDS)
Clinical Endocannabinoid Deficiency Syndrome is the theory that the stresses of modern life (in addition to genetic causes) are why some people may suffer from a variety of severe or chronic ailments. Such stresses and genetics may cause some people to not produce enough cannabinoids in their body.
If a person is deficient in cannaboids, their body’s endocannabinoid system may lack the tools to maintain a healthy state of balance. Over time, this could lead to someone developing severe issues such as:
- Chronic Pain
- Problems with Sleeping
- Anxiety Disorders
- Irritable Bowel Syndrome (IBS)
- Migraine Headaches
- Multiple Sclerosis
- Weakened Immune System
Restoring Our Body’s Natural Balance.
For those suffering from Clinical Endocannabinoid Deficiency Syndrome, supplementing with plant-based cannabinoids can give their body the tools to restore balance in the body. How CBD works is by replenishing the body with healthy levels of cannabinoids, those suffering from chronic or severe issues such as anxiety, sleep disorders, depression and pain may find significant or at least noticeable improvements to their quality of life.
Where can I get CBD?
Excited with how CBD works? Looking to try some? Made in BC with all-natural ingredients, our CBD products deliver the best in high-quality, effective and affordable in CBD care.
*Our goal is to deliver affordable cannabinoids to those need. We offer big savings through our assistance program for those with COVID Relief, veterans, students, disability, low-income status, and public safety workers.
Current Research On CBD:
Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of Experimental Medicine. 2012;209(6):1121-1134. doi:10.1084/jem.20120242.
Neelakantan, H., Tallarida, R.J., Reichenbach, Z.W., Tuma, R.F., Ward, S.J. and Walker, E.A., 2015. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behavioural pharmacology, 26(3), pp.304-314.Schizophrenia Research. 162 (1–3): 153–61.
Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz, 30(1), 47-61.
4.) Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire and Francisco Silveira Guimaraes. Current Pharmaceutical Design (2012) 18: 5131. Schizophrenia Research. 162 (1–3): 153–61.
Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR (January 2010). “Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology. 159 (1): 122–8. doi:10.1111/j.1476-5381.2009.00521.x.Schizophrenia Research. 162 (1–3): 153–61.
Hurd YL, Yoon M, Manini AF, et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015;12(4):807-815. doi:10.1007/s13311-015-0373-7.Schizophrenia Research. 162 (1–3): 153–61.
Lehmann, C., Fisher, N.B., Tugwell, B., Szczesniak, A., Kelly, M. and Zhou, J., 2016. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clinical hemorheology and microcirculation, 64(4), pp.655-662.Schizophrenia Research. 162 (1–3): 153–61.
Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6.
Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 23.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research. 162 (1–3): 153–61.
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (May 2005). “Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke. 36 (5): 1077–82. doi:10.1161/01.STR.0000163083.59201.34 Schizophrenia Research. 162 (1–3): 153–61.
Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). “Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005 Schizophrenia Research. 162 (1–3): 153–61.
Campos AC, Guimarães FS (August 2008). “Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology. 199 (2): 223–30. doi:10.1007/s00213-008-1168-x.Schizophrenia Research. 162 (1–3): 153–61.
Perucca E (December 2017). “Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?”. J Epilepsy Res. 7 (2): 61–76. doi:10.14581/jer.17012.
Scotter, E. L., Abood, M. E. and Glass, M. (2010), The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160: 480-498. doi:10.1111/j.1476-5381.2010.00735.xSchizophrenia Research. 162 (1–3): 153–61.
Esposito, G., De Filippis, D., Carnuccio, R. et al. J Mol Med (2006) 84: 253. https://doi.org/10.1007/s00109-005-0025-1Schizophrenia Research. 162 (1–3): 153–61.
Giacoppo, S., Pollastro, F., Grassi, G., Bramanti, P. and Mazzon, E., 2017. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia, 116, pp.77-84 Schizophrenia Research. 162 (1–3): 153–61.
Guindon, J. and Hohmann, A. G. (2011), The endocannabinoid system and cancer: therapeutic implication. British Journal of Pharmacology, 163: 1447-1463. doi:10.1111/j.1476-5381.2011.01327.xSchizophrenia Research. 162 (1–3): 153–61.
McAllister SD, Soroceanu L, Desprez P-Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2015;10(2):255-267. doi:10.1007/s11481-015-9608-y.Schizophrenia Research. 162 (1–3): 153–61.